atorvastatin has been researched along with plerixafor in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cai, A; Dong, Y; Feng, Y; Huang, Y; Mai, W; Qiu, R; Rao, S; Yu, D; Zheng, D; Zhou, Y | 1 |
1 review(s) available for atorvastatin and plerixafor
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for atorvastatin and plerixafor
| Article | Year |
|---|---|
SDF-1α upregulation by atorvastatin in rats with acute myocardial infarction via nitric oxide production confers anti-inflammatory and anti-apoptotic effects.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Atorvastatin; Benzylamines; Chemokine CXCL12; Coronary Vessels; Cyclams; Heptanoic Acids; Heterocyclic Compounds; Ligation; Male; Myocardial Infarction; NG-Nitroarginine Methyl Ester; Nitric Oxide; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; STAT3 Transcription Factor; Up-Regulation | 2012 |